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ABSTRACT
Disclosed are nanoparticles having a metallic core consisting
essentially of superparamagnetic iron oxide; a polymeric coat
surrounding said core, the coat having a matrix of polyacrylic
acid and forming an outer periphery of said nanoparticle; a
plurality of hydrophobic pockets formed by the polymeric
coat; a plurality of carboxylic groups along an outer periphery
of the polymeric coat and effective to conjugate with a predetermined targeting ligand which functionalizes the nanoparticle; a lipophylic fluorescent dye encapsulated in the plurality of hydrophobic pockets; and a drug encapsulated in the
plurality of hydrophobic pockets. Associated methods of
making the nanoparticles and of treatments using the nanoparticles are also disclosed.
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MULTIMODAL, MULTIFUNCTIONAL
POLYMER COATED NANOPARTICLES

capabilities and (e) a superparamagnetic iron oxide core for
magnetic resonance imaging (MRI).
Biocompatible, multimodal and theranostically functional
IONPs were synthesized using a novel water-based method
and demonstrated excellent properties for targeted cancer
therapy, optical and magnetic resonance imaging (MRI). For
the first time, a facile, modified solvent diffusion method is
used for the co-encapsulation of both an anti-cancer drug and
near infrared fluorescent dyes. The resulting folate-derivatized theranostic nanoparticles could allow for targeted optical/MR-imaging and targeted killing of folate expressing
cancer cells.
Specifically, our synthetic procedure differs from the previously reported methods in that the polymer is not present
during the initial nucleation process.[6-8] Instead, the polyacrylic acid is added at a later stage. This "step-wise" process,
as opposed to the "in-situ" process, allows for the formation
of stable, dispersed and highly crystalline superparamagnetic
ironoxidenanocrystals coated with PAA, (step 1, as shown in
FIG. 1). Successful coating with PAA was confirmed by the
presence of a negative zeta-potential g=-48 m V) and via
FT-IR analysis (as shown in FIG. 8). We then hypothesized
whether a hydrophobic dye could be encapsulated within the
hydrophobic pockets in the PAA coating, to thereby generate
multimodal IONPs with dual magnetic and fluorescent properties. As a proof-of-principle, we have encapsulated two
lipophilic fluorescent dyes (DiI or DiR) (step 2, as shown in
FIG. 1) using a modified solvent diffusion method.[9] These
dialkylcarbocyanine fluorophores (DiI, DiR) are widely used
in biomedical applications to label cell membranes and were
selected because of their high extinction coefficients (c> 125,
000 cm- 1 M- 1 ) and high fluorescence in hydrophobic environments.[9] The long chain dialkylcarbocyanine dye, DiR,
is of particular importance since it has an excitation/emission
near the infrared region (751/780), suitable for in vivo imaging.
Next, the IONPs (1, FIG. 1) were functionalized to yield a
propargylated nanoparticles (3, FIG. 1), which were later
used to generate multimodal folate-derivatized nanoparticles
(4, FIG. 1) via a highly selective 1,3-dipolar cycloaddition
reaction ("click" chemistry).[10] Thus, the water-soluble carbodiimide EDC, [1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride] was utilized to prepare the propargylated IONP (3, FIG.1), which is an important synthonforthe
synthesis of a library offunctional IONPs via "click" chemistry. Thepresenceofa weak 'C C'bandat2265 cm- 1 in the
FT-IR spectrum of these nanoparticles confirmed the presence of a propargyl (triple bond) group (FIG. 9).
As a model system, we conjugated the nanoparticles 3 with
an azide-functionalized folic acid[l 1] analog (FIG. 6) via
"click" chemistry. The resulting folate-decorated IONPs are
soluble in aqueous media and can encapsulate lipophilic fluorescent dyes. The presence of folic acid and dye in these
multimodal folate-derivatized nanoparticles (4, Scheme 1)
was confirmed through various spectrophotometric studies
(FIGS. 10-12). Furthermore, a hydrophobic anti-cancer drug
(paclitaxel, a.k.a. Taxol®) was encapsulated to yield a theranostic (therapeutic and diagnostic) nanoparticle with dual
imaging and therapeutic properties (5, Scheme 1). These
functional IONPs (1-5) were highly stable in aqueous solutions, as their magnetic relaxivity (R2), hydrodynamic diameter (D) and polydispersity index (PDI) remained unaffected
over a long period of time (Table 3). Therefore, the versatility
of the present method allows the generation of a small library
of multifunctional, multimodal and targetable IONPs.

RELATED APPLICATION
5

This application claims priority from co-pending provisional application Ser. No. 61/041,613, which was filed on 2
Apr. 2008, and to provisional application Ser. No. 61/161,
476, which was filed on 19 Mar. 2009 and is incorporated
herein by reference in its entirety.
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STATEMENT OF GOVERNMENT RIGHTS
Development of the present invention was supported, at
least in part, by a grant from the U.S. Government. Accordingly, the Government may have certain rights in the invention, as specified by law.

15

FIELD OF THE INVENTION
20

The present invention relates to the field of medical treatment of disease and, more particularly, to multimodal, multifunctional nanoparticles which serve as drug carriers for
targeted delivery and which can also be tracked by optical and
magnetic resonance imaging.

25

BACKGROUND OF THE INVENTION
Superparamagnetic iron oxide nanoparticles with dual
imaging and therapeutic capabilities hold great promise for
the non-invasive detection and treatment oftumors.[1] When
conjugated with tumor-specific targeting ligands, these multifunctional nanoparticles can be used to specifically deliver
anti-cancer drugs to tumors, thereby minimizing severe side
effects.[2] To meet the demand for the rapid development and
potential clinical application of targeted anti-cancer nanotherapies, it is desirable to introduce optical (fluorescent)
imaging capabilities to these nanoparticles to facilitate noninvasive assessment of drug homing and efficacy. This is often
achieved by crosslinking the polymeric coating surrounding
the nanoparticle and functionalizing its surface with amine or
carboxyl groups that are then used to conjugate fluorescent
dyes and drugs. [3] This approach to introduce multimodality
(magnetic and fluorescent)[4] and multifunctionality (imaging and therapeutic)[5] to iron oxide nanoparticles (IONPs),
although widely used, often compromises the solubility of the
nanoparticles in aqueous media and reduces the number of
available functional groups that otherwise could be used to
attach ligands for targeting applications.
SUMMARY OF THE INVENTION
With the foregoing in mind, the present invention advantageously provides iron oxide nanoparticles (IONPs) wherein
a lipophilic near infrared (NIR) dye and an anti-cancer drug
are co-encapsulated within hydrophobic pockets formed in a
polymeric matrix of polyacrylic acid (PAA) which coats the
nanoparticles (PAA-IONPs). The resulting composition is
useful for combined optical imaging, MRI detection and targeted cancer therapy.
Our water-based and green chemistry approach to synthesizing these nanoparticles has five components (a) an encapsulated chemotherapeutic agent effective in cancer therapy
(for example, paclitaxel, also known by the tradename Taxol),
(b) a surface functionality (folic acid ligand) for cancer targeting, (c) "click"-chemistry-based conjugation of targeting
ligands, (d) an encapsulated NIR fluorescent dye for imaging
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BRIEF DESCRIPTION OF THE DRAWINGS
65

Some of the features, advantages, and benefits of the
present invention having been stated, others will become
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apparent as the description proceeds when taken in conjunction with the accompanying drawings, presented for solely
for exemplary purposes and not with intent to limit the invention thereto, and in which:
FIG. 1 is a schematic representation of the synthesis of
theranostics andmultimodal IONPs according to an embodiment of the present invention; click chemistry and carbodiimide chemistry have been used for the synthesis of a library
of functional IONPs; NIR dyes and paclitaxel coencapsulated
IONPs were prepared in water using the modified solvent
diffusion method detailed below;
FIG. 2 shows the characterization of multimodal nanoparticles 2 (PAA-IONP-DiI);A) determination ofhydrodynamic
diameter of the IONPs through Dynamic Light Scattering
(DLS), Inset: Transmission Electron Microscope (TEM)
image of the corresponding nanoparticles (scale bar 100 nm.);
B) magnetic hysteresis loops at 300 and 5 K, showing nanoparticles are superparamagnetic; C) fluorescence emission
spectra (in PBS buffer) ofDiI dye encapsulated IONPs 2 and
that of 1 without any dye; D) fluorescence emission spectra of
2 and that of free non-encapsulated DiI in solution;
FIG. 3 shows a determination of cytotoxicity of the functional IONPs: carboxylated [COOH (2)], propargylated
[PROPARGYL (3)], folate-conjugated [FOLATE (4)] and
Taxol-carrying [TAXOL (5)]; control (CTRL) cells: A) Lung
carcinoma cells (A549) and B) Cardiomyocyte cells (H9c2)
were treated with PBS; average values of four measurements
are depicted±standard error;
FIG. 4 depicts an assessment ofIONPs' cellular uptake via
confocal laser-scamiing microscopy using lung carcinoma
A549 cells;A) no internalization was observed in cells treated
with carboxylated IONPs (2), as no DiI fluorescence was
observed in the cytoplasm; B) enhanced internalization was
observed upon incubation with the folate-immobilized
IONPs (4); C) Taxol® and DiI co-encapsulated folate-functionalized IONPs (5) induced cell death; (D-F) corresponding
merged confocal images of the functional IONPs treated cells
with their nucleus stained with DAPI (blue);
FIG. 5 shows drug and dye release profiles of functional
IONPs (5) in PBS (pH=7.4) at 37° C.; release ofTaxol® (A&
B) and DiI (C & D) was observed in the presence of an
esterase enzyme (A & C) and at pH 4.0 (B & D);
FIG. 6 illustrates synthesis of folate conjugated PAAIONPs using carbodiimide chemistry and "click" chemistry;
FIG. 7 shows a High Resolution Transmission Electron
Microscope (HR-TEM) image of the polyacrylic acid coated
iron oxide nanoparticles (PAA-IONPs, 2); scale bar 300 nm;
FIG. 8 is an FT-IR spectroscopic analysis of the synthesized IONPs (1, PAA-IONP, red line) and polyacrylic acid
(PAA, black line); presence of the band at 1685 cm- 1 in 1
confirms the presence of a PAA coating in the IONPs;
FIG. 9 are FT-IR spectra of propargylated nanoparticles (3,
IONP-PAA-C2, black line) and carboxylated IONP (1,
IONP-PAA, red line); presence of a weak band at 2265 cm- 1
confirms the presence of propargyl groups in IONPs 3;
FIG.10 shows spectrophotometric characterizations of the
folate-conjugated PAA-IONPs (3a); a) UVNis spectrum of
3a showing absorbance at 352 nm, indicating the presence of
folic acid on the iron oxide nanoparticles; b) fluorescence
emission spectrum (a.u.) of 3a showing the characteristic
fluorescent emission at 441 nm and confirming the presence
offolic acid on the nanoparticles;
FIG. 11 depicts UV/Vis spectra of a) DiI encapsulated
IONPs (2) and b) corresponding DiR encapsulated IONPs
(2-DiR) showing the presence of encapsulated DiI (555 nm)
and DiR (754 nm) inside the PAA coating ofIONPs;

FIG. 12 presents spectrophotometric characterizations of
the DiI encapsulated folate clicked IONPs (4); a) UVNis
spectrum showing absorbance at 352 nm and 555 nm indicating the presence of folic acid and DiI dye, respectively; b)
Fluorescence emission spectrum (a.u.) showing intensity
maximum at 441 nm and 581 nm confirmed for the "click"
chemistry with folic acid and effective encapsulation of DiI
dye; similar results were obtained for paclitaxel and DiI
encapsulated folate conjugated IONPs;
FIG. 13 provides fluorescence emission spectra (a.u.)
showing intensity maximum at 445 nm for Taxol® encapsulated IONPs (5) and 375 nm for free Taxol®, confirming the
presence of the drug inside the PAA polymer coating of the
iron oxide nanoparticles;
FIG. 14 depicts epifluorescence images of A) live and B)
fixed lung carcinoma cells (A549) after incubation of folatedecorated IONPs (4) for 3 h; cell internalization (A549) and
cytoplasmic localization is observed either in live or fixed
cells; similar results were observed in the case of non-cancerous cell (cardiomyocytes) lines; nucleus stained with DAPI
(blue color);
FIG. 15 shows confocal images of a) lung carcinomaA549
cells pre-incubated (saturated, no free folate receptor) with
free folic acid (100 µL, 10 mg/mL) and then incubated with
folate-IONPs (4, 50 µL, 1.1 mg/mL) and free folic acid (50
µL, 10 mg/mL ); b) cardiomyocyte cells (H9c2, no folate
receptor) incubated with folate-IONPs (4, 50 µL, 1.1
mg/mL); no internalization was observed due to absence of
free folate receptors (a, A549) or absence offolate receptors
(b, H9c2); these observations confirmed the targeting capability and receptor mediated endocytosis of our theranostic
IONPs; cells incubated for 3 h with functional IONPs 4 and
the nuclei were stained with DAPI (blue);
FIG. 16 shows NIR fluorescence imaging of lung carcinoma cells (A549) incubated with (A) carboxylated IONPs
(2-DiR) or (B) folate conjugated IONPs (4-DiR); images
were taken using an ICG filter;
FIG. 17 is a dual image of DiI and DiR wherein (A) is a
composite fluorescence optical image of 4-DiI and 4-DiR,
taken in separate tubes, showing the imaging capability of the
both IONPs; fluorescence images were taken by scanning the
entire wavelength from 480 to 920 nm and performing spectral unmixing; (B) Dual image of DiI and DiR using the
MAESTRO optical imager; it shows the combined image as
an overlay of both images in the lower row (D and E); WL
indicates the White Light image; DiI was obtained at 595 nm
and DiR at 780 nm; and
FIG. 18 is an MR image (T2 map) of a PAA-IONP 4
encapsulating either DiI or DiR (4-DiI or 4-DiR); these MR
images were obtained by making dilutions from a stock (100
µg/mL) nanoparticle suspension and comparing their MRI
signal with that of water; the color bar indicates the T2 relaxation time in ms.
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DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENT
The present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
which preferred embodiments of the invention are shown.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or
testing of the present invention, suitable methods and materials are described below. Any publications, patent applica-

US 8,236,284 B 1
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tions, patents, or other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the
present specification, including any definitions, will control.
In addition, the materials, methods and examples given are
illustrative in nature only and not intended to be limiting.
Accordingly, this invention may be embodied in different
forms and should not be construed as limited to the illustrated
embodiments set forth herein. Rather, these illustrated
embodiments are provided so that this disclosure will be
thorough and complete, and will fully convey the scope of the
invention to those skilled in the art. Other features and advantages of the invention will be apparent from the following
detailed description, and from the claims.
Materials and Methods:
Iron salts: FeC1 2 .4H 2 0 and FeCl 3 .6H 2 0, animonium
hydroxide, hydrochloric acid, folic acid, DMF, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
esterase (from porcine liver, 16.5 mg protein/mL of Biuret,
177 units/mg of protein), N-hydroxysuccinimide (NHS),
polyacrylic acid and other chemicals were purchased from
Sigma-Aldrich. Dialky lcarbocyanine fluorescent dyes (DiID282 and DiR-D12731) and 4', 6-diamidino-2-phenylindole (DAPI-D1306) were purchased from Invitrogen, EDC
(1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) was obtained from Pierce Biotechnology. The
human lung carcinoma A549 (CCL-185) and cardiomyocyte
(H9c2) cell lines were obtained from ATCC. Dialysis membranes were obtained from Spectrum Laboratories. Nitrogen
purged DI water was used in the synthesis.
Instrumentation: Infrared spectra were recorded on a
PerkinElmer Spectrum 100 FT-IR spectrometer. UV/Vis
spectra were recorded using CARY 300 Bio UVNis spectrophotometer. Fluorescence spectra were recorded on a
NanoLog Horiba Jobin Yvon spectrophotometer. NMR spectrum was recorded on a MERCURY 300 MHz spectrometer
using the TMS/solvent signal as an internal reference.
Dynamic light scattering (DLS) studies were done using a
PDDLS/Coo!Batch 40T instrument using Precision Deconvolve 32 software. High throughput absorbance readings for
MTT assays were done using a BIO-TEK Synergy HT multidetection microplate reader. The core size and morphology of
the nanoparticles were characterized by using high resolution
transmission electron microscopy (HRTEM, FEI Technai
F30). Overall surface charge (zeta potential) of IONP was
measured using Zetasizer Nano ZS from Malvern Instruments. Transverse (T2) proton relaxation times measurements were done using a Bruker Minispec mq20 NMR analyzer operating at a magnetic field of 0.47 T and at 37° C.
Fluorescent images of nanoparticles in solution were performed using a Maestro CIRL optical imaging scarmer. Magnetic resonance images of nanoparticles in solution were
performed using a 4.7 T Bruker horizontal bore small animal
MR scarmer.
Synthesis of Azide-Functionalized Folic Acid (7,
Folate-N3) by Carbodiimide Chemistry

-continued
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The scheme for synthesis of azido-folic acid (7) from chloropropyl amine is shown above.
Synthesis of Aminopropylazide (6): In a 100 mL round
bottom flask, chloropropyl amine (7.0 g, 75.26 mmol) and
sodium azide (14 .23 g, 225. 81 mmol) were added to 40 mL of
distilled water and heated at 80° C. for 20 h. The reaction
mixture was concentrated in a rotary evaporator at high
vacuum, 2 g of KOH were added and the product was
extracted using diethyl ether.
Subsequently, the reaction mixture was dried over anhydrous sodium sulphate and concentrated. Finally, the product
was purified via flash column chromatography using 4%
ethyl acetate in petrolium ether as an eluant. Yield: 5.1 g
(68%). 1H NMR (300 MHz, CDC1 3 , d ppm): 1.26 (bs, 2H),
1.81 (m, 2H), 2.80 (t, 2H), 3.38 (t, 2H). FT-IR(CHC1 3 ): 3307,
2941,2089, 1663, 1433, 1370, 1259, 1242, 1075, 1026,818,
760 cm- 1 .
Synthesis of azide-functionalized folic acid (7): To a solution offolic acid (0.05 g, 0.12 mmol) in DMSO (2 mL), EDC
(0.021 g, 0.11 mmol) and NHS (0.013 g, 0.11 mmol) in 0.5
mL MES buffer (pH=5.0) were added and then incubated at
room temperature for 3 minutes. To this resulting reaction
mixture was added drop-wise ethylenediamine (0.007 g, 0.11
mmol) in 0.25 mL of PBS (pH=7.4) and then incubated for3
hat room temperature. The reaction mixture was centrifuged
and washed to remove excess starting materials. The azidefunctionalized folic acid was dissolved in 1 mL ofDMF until
further use. Yield: 0.05 g (86%). The presence of a band at
2097 cm- 1 in the IR spectrum and a UV absorbance shoulder
at 354 nm confirmed the formation of azide-functionalized
folic acid. 1H NMR (400 MHz, DMSO-d6, d ppm): 1.61 (m,
2H), 1.65 (m, 2H), 1.90 (m, 2H), 2.19 (t, 2H), 2.78 (t, 2H),
4.18 (q, lH), 4.21(d,2H), 6.62 (d, 2H), 7.59 (d, 2H), 8.58 (s,
lH). FT-IR: 3024, 2097, 1685, 1603, 1492, 1375, 1291, 1248,
1180, 1122, 1062, 950, 844, 755, 696 cm- 1 .
Synthesis of PAA-IONPs (1): For the water-based, stepwise synthesis of polyacrylic acid-coated iron oxide nanoparticles (PAA-IONPs), three solutions were prepared; an iron
salt solution [0.62 g ofFeCly6H 2 0 and 0.32 g ofFeCl 2 .4H20
in dilute HCl solution (100 µL of12 N HCl in 2.0mL H 2 0)];
an alkaline solution [1.8 mL of30% NH4 0H solution in 15
mL ofN2 purged DI water]; and a stabilizing agent solution
[820 mg ofpolyacrylic acid in 5 mL of DI water]. To synthesize the PAA-IONP, the iron salt solution was added to the
alkaline solution under vigorous stirring. The resulting dark
suspension of iron oxide nanoparticles was stirred for
approximately 30 seconds before addition of the stabilizing
agent solution and stirred for 1 h. The resulting suspension of
PAA-IONPs was then centrifuged at 4000 rpm for 30 minutes
and the supernatant was washed three times with DI water to
get rid of free polyacrylic acid and other unreacted reagents
using an Amicon 8200 cell (Millipore ultra-filtration membrane YM-30 k). Finally, the PAA-IONP suspension was
purified using magnetic column, washed with phosphate
buffer saline (pH=7.4) and concentrated using the Amicon
8200 cell system. The iron concentration and magnetic relaxation of the PAA-IONPs was determined as previously
reported [Josephson et. al. Bioconjugate Chem 1999, 10,
186-191]. The successful coating of the IONPs with PAA was
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confirmed by the presence of a negative zeta-potential (s=-48
mV) and the characteristic acid carbonyl bands on the FT-IR
spectroscopic analysis of the nanoparticles (FIGS. 6 and 8).
Synthesis of propargylated IONPs (3): Carbodiimide
chemistry. To a suspension of PAA-IONP (1) (45 mg Fe) in
MES buffer (26 mL, pH=6), a solution of EDC (87 mg, 10
mmol) and NHS (52 mg, 10 mmol) in MES buffer (2 mL) was
added and incubated for 3 minutes. To the resulting reaction
mixture, propargylamine (25mg, lOmmol)inDMF (0.5 mL)
was added drop-wise and incubated for 5 hat room temperature. The resulting reaction mixture was then purified using
magnetic colunm and then using amicon 8200 cell (Millipore
ultra-filtration membrane YM-30 k) to get rid of unreacted
propargyl chloride and other unreacted reagents and kept in
PBS at 4° C. FT-IR data analysis (FIG. 9) confirms the
completion and success of the conjugation.
General procedure for dye-encapsulated functional IONPs
(2, 4 ): Modified solvent diffusion method. To a suspension of
IONPs (4.5 mL, [Fe]=l.1 mg/mL) in PBS, a solution of the
corresponding dialkylcarbocyanine fluorescent dyes (DiI or
DiR, 0.1 µg/µL) in DMF was added drop-wise at room temperature with continuous stirring at 1000 rpm. The resulting
dye-encapsulated IONPs were purified using a magnetic colunm and then dialyzed (using 6-8 K molecular weight cut off
dialysis bag) three times against deionized water and finally
against phosphate buffered saline solution. The successful
encapsulation of the corresponding dye (DiI or DiR) on the
PAA-IONPs was confirmed by UVNis spectrophotometric
measurements (FIG. lOa-b). In addition, when these nanoparticles were functionalized with folate, the presence of both
folate and dye encapsulated groups were assessed by UV/Vis
(FIG. 12a) and fluorescence (FIG. 12b) spectrometry.
Procedure for co-encapsulation of Paclitaxel and Oil into
IONPs (5): A solution containing paclitaxel (5 µL, 0.05
µg/µL) andDiI dye (5 µL, 0.1 µg/µL) in500 µLDMFwas used
and the same modified solvent diffusion method was followed as described above. The presence of Taxol® in the
IONPs (5) was confirmed by using fluorescence spectrophotometer (FIG. 13).
Synthesis of3a: Folate conjugation using Click chemistry.
To a suspension of propargylated IONPs 3 (13 mg Fe) in
bicarbonate buffer (pH=8.5), a catalytic amount ofCuI (0.06
µg, 3x 10-10 mmol) were added for a total volume of 125 µL
of bicarbonate buffer and vortexed for 30 seconds. Then, a
solution of azide-functionalized folic acid (7, Formula
I-above, 0.003 g, 6x10-2 mmol) in DMSO was added and
incubated at room temperature for 12 h. The final reaction
mixture was purified by using magnetic column and by dialysis using 6-8 K molecular weight cut off dialysis bag, against
deionized water first and a finally with a phosphate buffered
saline (PBS) solution. The purified functional IONPs were
stored at 4 ° C. until further use. The successful conjugation of
folic acid with PAA-IONPs was confirmed by UVNis (FIG.
lOa) and fluorescence (FIG. lOb) spectrophotometric measurements.
Cell culture and cell viability studies: MTT assay. The lung
carcinoma cells (A549) and cardiomyocytes (H9c2) were
obtained fromATCC, USA. Lung carcinomas were grown in
Kaighn's modification of Ham's F12 medium (F12K--Cellgro ), supplemented with 5% fetal bovine serum (Heat-inactivated FBS--Cellgro ), L-glutamine, streptomycin, amphotericin B, and sodium bicarbonate. The cells were maintained
at 37° C., 5% C02 in a humidified incubator. Cardiomyocyte
cells were grown in Eagle's Minimal Essential medium
supplemented with 10% fetal bovine serum, sodium pyruvate, L-glutamine, penicillin, streptomycin, amphotericin B
and sodium bicarbonate. For MTT assay, lung carcinoma and

cardiomyocyte cells (2,500 cells/well) were seeded in
96-well plates, and were incubated with the IONPs for 3 hat
37° C. Then, each well was washed three times with lxPBS
and treated with20 µL MTT (5 µg/µl, 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide, Sigma-Aldrich) for
2 h. The resulting formazan crystals were dissolved in acidified isopropanol (0.1 N HCl) and the absorbance was
recorded at 570 nm and 750 nm (background), using a Synergy HT multi-detection microplate reader (Biotek). These
experiments were performed in triplicate.
Cellular internalization: Confocal Microscopy and IVIS
experiments. A Zeiss LSM 510 confocal and Zeiss Axiovert
200 epifluorescence microscopes were used to assess the
uptake offolate-derivatized IONPs by the human lung carcinoma (A549) cell line. Specifically, A549 cells (10,000) were
incubated with the corresponding IONPs preparation (1.1
mg/mL) for 3 h in a humidified incubator (37° C., 5% C0 2 ).
Subsequently, the cells were thoroughly washed three times
with 1xPBS and fixed with 10% formalin solution. Nuclear
staining with DAPI was performed as recommended by the
supplier. Then, multiple confocal images were obtained,
achieving a representative view of the cell-IONPs interaction.
For the IVIS analysis, 10,000 lung carcinoma cells were
incubated for 3 h with the corresponding IONPs and the
supernatant was collected in EppendorfTubes®. Cells were
thoroughly washed with 1xPBS and detached them, as stated
above. The resulting pellets were resuspended in 1 mL culture
media. All Eppendorf Tubes® were examined simultaneously on a Xenogen® IVIS system, using the ICG filter for
DiR dye. All experiments were performed in triplicate.
In Vitro drug/dye release: The in vitro drug/dye release
studies were carried out using a dynamic dialysis technique at
37° C. Briefly, 100 µL of IONPs (5) are incubated with a
porcine liver esterase (20 µL) inside a dialysis bag (MWCO
6000-8000), which is then placed in a PBS solution (pH 7.4).
The amount of guest (dye or drug) molecules released from
the nanoparticle into the PBS solution was determined at
regular time intervals by taking 1-mL aliquots from the PBS
solution and measuring the fluorescence intensity at 581 nm
for DiI and 375 nm for Taxol®. The concentration of the
either dye or drug was calculated using a standard calibration
curve. The cumulative fraction of release versus time was
calculated using the following equation:
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Where [guest ]t is the amount of guest released at time t,
[guest]total is the total guest present in the guest encapsulated
IONPs.
TABLE 1

50
IONPs

55

R1
D
(PD!)
R1
D
(PD!)

60

R1
D
(PD!)
R1
D
(PD!)

65

2
206 ± 2
86
(0.89) ±
1
206 ± 1
86
(0.89) ±
2
208 ± 3
88
(0.91) ±
2
210 ±4
87
(0.95) ±
4

202 ± 3
90
(0.87) ±
2
201±2
91
(0.88) ±
3
202 ±4
91
(0.90) ±
4
204 ±4
92
(0.92) ±
5

4
207 ± 2
87
(0.89) ±
1
207 ± 3
87
(0.92) ±
2
208 ± 2
89
(0.88) ±
2
207 ± 3
88
(0.91) ±
4

204 ± 3
94
(0.87) ±
3
204 ± 2
94
(0.88) ±
3
203 ± 3
95
(0.91) ±
4
205 ±4
96
(0.89) ±
4

Time
203 ± 5
96
(0.91) ±
3
204 ±4
96
(0.90) ±
4
205 ± 5
98
(0.91) ±
4
208 ± 5
100
(0.88) ±
5

15
Days

Month

Months

Months
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Table 1 shows Magnetic relaxivity (R2, s31 1 mM- 1 ), Hydrodynamic diameter (D, m) and Polydispersity index (PDI) of
all the functional iron oxide nanoparticles (IONPs) over the
period of time, showing the stability of the functional IONPs
(1-5) in aqueous buffered solution.
Proof ofFolate Receptor Mediated Internalization: Confocal
Microscopy and IVIS Experiments.
A Zeiss LSM 510 confocal fluorescence microscope was
used to assess the uptake offolate-derivatized IONPs by the
human lung carcinoma (A549) cell line. Specifically, A549
cells (10,000) were incubated with the corresponding IONPs
preparation (1.1 mg/mL) for 3 h in a humidified incubator
(37° C., 5% C0 2 ).
Subsequently, the cells were thoroughly washed three
times with 1xPBS and fixed with 10% formalin solution.
Nuclear staining with DAPI was performed as recommended
by the supplier. Then, multiple confocal images were
obtained, achieving a representative view of the cell-IONPs
interaction (FIG. 15).
To prove that internalization was mediated by the folate
receptor, A549 cells were pre-incubated with free folate (to
saturate the folate receptor) and then treated with the folate
derivatized IONP (4). Results show no significant internalization of the nanoparticles (FIG. 15a). Furthermore, no internalization of 4 was observed when H9c2, a cardiomyocyte
cell line that does not express the folate receptor, was used
(FIG. 15b).
Fluorescence Imaging ofMultimodal Nanoparticles in Solution.
To assess the potential application of the multimodal nanoparticles 4, in vivo, encapsulating either DiI or DiR, (4-DiI or
4-DiR), a Maestro CIRL (Woburn, Mass.) was used. Furthermore, a 1: 1 mixture of the DiI and DiR nanoparticles was
prepared and image. Results show the capability of imaging
both nanoparticles simultaneously.
Discussion
Specifically, our synthetic procedure differs from the previously reported methods in that the polymer is not present
during the initial nucleation process.[6-8] Instead, the polyacrylic acid is added at a later stage. This "step-wise" process,
as opposed to the "in-situ" process, allows for the formation
of stable, disperse and highly crystalline superparamagnetic
ironoxidenanocrystals coated with PAA, (See 1, FIG.1). The
successful coating with PAA was confirmed by the presence
ofa negative zeta-potential (s=-48 m V) and via FT-IR analysis (See FIG. 8).
We then hypothesized whether a hydrophobic dye could be
encapsulated within the hydrophobic pockets in the PAA
coating, generating multimodal IONPs with dual magnetic
and fluorescent properties. As a proof-of-principle, we have
encapsulated two lipophilic fluorescent dyes (DiI or DiR)
(See 2, FIG. 1) using a modified solvent diffusion method. [9]
These dialkylcarbocyanine fluorophores (DiI, DiR) are
widely used in biomedical applications to label cell membranes and were selected because of their high extinction
coefficients (c> 125,000 cm- 1 M- 1 ) and high fluorescence in
hydrophobic environments.[9] The long chain dialkylcarbocyanine dye, DiR, is of particular importance since it has an
excitation/emission near the infrared region (751/780), it is
suitable for in vivo imaging.
Next, the IONP 1 was functionalized to yield a propargylated nanoparticle (See 3, FIG. 1), which was later used to
generate a multimodal folate-derivatized nanoparticle (See 4,
FIG. 1) via highly selective 1,3-dipolar cycloaddition reaction ("click" chemistry).[10] Thus, the water-soluble carbodiimide EDC [11], [1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride] was utilized to prepare the

propargylated IONP (See 3, FIG. 1), which is an important
synthon for the synthesis of a library of functional IONPs via
"click" chemistry. The presence of a weak 'C C' band at
2265 cm- 1 in the FT-IR spectrum of these nanoparticles confirmed the presence of a propargyl (triple bond) group (See
FIG. 9).
As a model system, we conjugated the nanoparticle 3,
illustrated in FIG. 1, with an azide-functionalized folic acid
analog (See also FIG. 6 and synthesis of azide-functionalized
folic acid, above) via "click" chemistry. The resulting folatedecorated IONPs are soluble in aqueous media and can
encapsulate lipophilic fluorescent dyes. The presence of folic
acid and dye in these multimodal folate-derivatized nanoparticles (See 4, FIG. 1) was confirmed through various spectrophotometric studies (See FIGS. 10-12). Furthermore, a
hydrophobic anti-cancer drug (paclitaxel, a.k.a. Taxol®) was
encapsulated to yield a theranostic (therapeutic and diagnostic) nanoparticle with dual imaging and therapeutic properties
(See 5, FIG. 1). These functional IONPs (1-5) were highly
stable in aqueous solutions, as their magnetic relaxivity (R2),
hydrodynamic diameter (D) and polydispersity index (PDI)
remained unaffected over a long period of time (See Table 3).
Therefore, the versatility of our method allows the generation
of a small library of multifunctional, multimodal and targetable IONPs.
Dynamic light scattering (DLS) studies of the functional
PAA-IONP (2) confirmed the presence of stable and monodispersed nanoparticles with a hydrodynamic diameter of 90
nm (FIG. 2A), while TEM experiments revealed an iron oxide
core of 8 nm (Inset: FIG. 2A; see also FIG. 7). These measurements suggest the formation of a thick polymeric coating
(-40 nm) around the iron oxide core, which plays a key role
in the encapsulation of hydrophobic guest molecules. FT-IR
analysis further confirmed the presence of the PAA coating
and carboxylic acid groups on 1, as well as the corresponding
surface propargyl groups on nanoparticle 3 (See FIGS. 8-9).
Magnetic hysteresis loops (FIG. 2B) corroborated the superparamagnetic nature of the nanoparticles, while water relaxation measurements using a 0.47T Bruker's Minispec relaxometer indicated the presence of magnetic IONPs with high
water relaxation (Rl =53 s- 1 mM- 1 , R2=202 s- 1 mM- 1 ). The
incorporation of a hydrophobic dye into 1 was done using a
modified solvent diffusionmethod.[9] Specifically, a solution
ofDiI in DMF (0.1 µg/µL) was added drop-wise to a stirring
aqueous nanoparticle suspension (4.5 mL and [Fe]=l.1
mg/mL). The slow addition of the dye solution allows forthe
rapid diffusion ofDMF into the aqueous medium, causing the
dye to become encapsulated in the hydrophobic microdomains of the PAA coating. The presence of an absorption
maximum at 555 nm in the UV/Vis spectrum (See FIG. lla)
and a corresponding fluorescence emission peak at 595 nm
(FIG. 2C) confirmed the presence ofDiI in the nanoparticle.
Furthermore, the encapsulation of DiI was confirmed by the
presence of a 14 nm red-shift in the fluorescence intensity
maximum of the Dil-encapsulating PAA-IONP, as compared
to the free DiI (581 nm, FIG. 2D). Similar red-shifts have
been previously reported in other systems, indicating an interaction of the fluorescent guest molecule with the electronic
environment of the encapsulating pocket.[12] Next, we
encapsulated both DiI and Taxol® to the folate-conjugated
nanoparticle for dual cellular imaging and targeted cancer
therapy. To synthesize such nanoparticle (5), a DMF solution
containing DiI (0.1 µg/µL) and Taxol® (0.05 µg/µL) was
added to a stirring solution offolate-derivatized PAA-IONPs
(See compound 3a in FIG. 6). Since the dye and the drug are
hydrophobic, we expected both molecules to become encapsulated. The encapsulation ofTaxol® was confirmed through
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fluorescence spectroscopy (FIG. 13). Furthermore, the
amount of dye, folic acid and Taxol® molecules per nanoparticle was calculated, as previously described [13] (Table 2).
These dye-encapsulating PAA-IONPs were highly stable in
aqueous solutions for more than a year, without significant
reduction in the fluorescence emission of the encapsulated
dyes. Additionally, no leaching of the encapsulated dye from
the nanoparticle occurred, as no precipitation of the dye was
observed after prolonged storage in PBS, pH 7.4.

These results were also observed in experiments performed
using live (non-fixed) A54 9 cells, where internalization of the
folate-decorated IONPs (4) was monitored through fluorescence microscopy (See FIG. 14). The enhanced cellular
uptake of the folate-decorated nanoparticle (4) inA549 cells
may have been attributed to folate-receptor mediated internalization. As internalization of 4 was nominal in A549 cells
pre-incubated with free folate and in studies using the H9c2
cardiomyocyte cell line (FIG. lS), we corroborated the receptor-mediated internalization of our folate-decorated IONPs
(4). Next, we investigated the cellular uptake of a multifunctional folate-conjugated nanoparticle (5) with dual imaging
and targeted cancer therapeutic properties. When these
IONPs were incubated with A549 cells, mitotic arrest was
observed, leading to dramatic cellular morphological
changes and cell death (FIGS. 4C and 4F).
The therapeutic application of our nanoparticles depends
on the rate ofrelease of the encapsulated drug from the PAA
coating. To evaluate S's drug release profile, enzymatic (esterase) and low-pH degradation experiments were performed.
Results indicated a fast release of the drug (Taxol®) from the
nanoparticle (5) upon esterase incubation, reaching a plateau
within 2 hours (FIG. SA). An even faster release of the drug
was observed at pH 4.0, reaching a plateau within 30 minutes
(FIG. SB). No significant release of the drug was observed
from nanoparticles incubated in PBS, pH 7.4. These results
are significant as they demonstrate the stability of the nanoparticles during storage (PBS), and their cargo release only
after cellular uptake via either esterase-mediated degradation
or in acidified lysosomes. Therefore, only after its folatereceptor-mediated uptake, the nanoparticle 5 becomes cytotoxic upon intracellular release of its cargo therapeutic agent.
Interestingly, a much slower release of the dye was observed,
both upon esterase incubation and at pH 4.0
(FIGS. SC and SD). However, no release of the dye was
observed at normal physiological pH (7.4). The observed
differential release of the drug vs. the dye from IONP 5 may
be attributed to the drug's (Taxol®) size and hydrophobic
nature.
Taken together, these results make our folate-decoratedIONP (5) an important drug carrier, as it can rapidly release
Taxol® and therefore induce cell death only upon targeted
cell internalization. Furthermore, the acidic microenvironment of most tumors could enhance the release ofTaxol® and
dye from the nanoparticle into the tumor to facilitate the
monitoring of tumor regression by MR and optical imaging.
Also, by modifying the targeting moiety of the theranostic
IONP's surface, other carcinomas may be targeted, while
obtaining important spatiotemporal information for clinical
decision making.
For in vivo imaging applications, nanoparticles with excitation and emission in the near infrared region (650-900 nm)
are needed for deep tissue fluorescence imaging.[ 17] Towards
this end, we encapsulated a near infrared dialky lcarbocyanine
dye (DiR, excitation/emission:751/780 nm) into the carboxylated (2-DiR) and folate-conjugated (4-DiR) IONPs, following the same synthetic protocol described for the synthesis of
IONPs 2 and 4. UV/Vis studies corroborated the presence of
the near infrared DiR dye within the nanoparticle's PAA
coating (FIG. llb ). To demonstrate the targeting capability of
our functional near-infrared and folate-derivatized IONP
(4-DiR) to folate receptor expressing cells and eventually
assess their intracellular activity, we incubated A549 lung
carcinoma cells with the (4-DiR) nanoparticle andimaged the
cells using fluorescence imaging techniques.
In these studies, A549 cells (10,000 cells) were treated with
either DiR-carrying carboxylated (2-DiR) or DiR-carrying
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TABLE2
Determination of magnetic relaxivity (R2), hydrodynamic diameter (D)
and polydispersity index (PD!) of functional IONPs immediately after
synthesis. Quantitative estimation of amount of dye, folic acid and
Taxol ® per iron crystal of the corresponding
multifunctional IONPs (1-5).
R1

IONPs

s- 1 mM- 1

206 ± 2
2

202 ± 3
207 ± 2

4

204 ± 3
203 ± 5

D (PD!)
nm
86
(0.89) ± 1
90
(0.87) ± 2
87
(0.89) ± 1
94
(0.87) ± 3
96
(0.91) ± 4

Dye/
IONPs

Folate/
IONPs

15

Taxol/
IONPs
20

31±2

28 ± 2

12 ± 2

19 ± 1

12 ± 2

25
11±3

To evaluate the potential biomedical applications of the
Dil-encapsulating IONPs (2, 3, 4 and 5, 1.1 mg/mL), we
assessed their potential cytotoxicity, via the MTT assay (FIG.
3). Therefore, we examined the in vitro differential cytotoxicity of carboxylated (COOH, 2), propargylated (PROPARGYL, 3), folate-decorated (FOLATE, 4), folate-decorated
and taxol-encapsulating IONPs (TAXOL®, 5), using lung
carcinoma (A549, 2,500 cells/well) (FIG. 2A) and cardiomyocyte cell lines (H9c2, 2,500 cells/well) (FIG. 2B). Carboxylated, propargylated and folate-conjugated IONPs
exhibited nominal cytotoxicity (less than3% compared to the
control) towards both cell lines after a 3 h incubation. On the
other hand, incubation with the folate-decorated and taxolcarrying IONPs ( 5) resulted in an 80% reduction in the viability of the lung carcinoma (A549) cell line. In contrast, no
significant reduction in cell viability was observed when cardiomyocytes (H9c2) which do not overexpress the folate
receptor[14] were incubated with 5. These results demonstrate that nanoparticles 1-4 were not toxic to either A549 or
H9c2 cells, hence these nanoparticles can be used as effective
multimodal imaging agents. However, as IONP 5 was only
cytotoxic to cancer cells (A549) that overexpress folate
receptor,[15,16] it can be utilized as a potential targeted multifunctional (imaging and therapeutic) nanoagent for the
treatment of folate-receptor-expressing tumors.
To further explore the potential biomedical applications of
the synthesized functional PAA-IONPs, we evaluated the
selective uptake of the folate-functionalized nanoparticle (4)
by A549 lung cancer cells, as these cells overexpress the
folate receptor. In these experiments, carboxylated (2) or
folate-conjugated (4) nanoparticles (1.1 mg/mL) were incubated with A549 cells (10, 000 cells) for 3 h, washed to
remove non-internalized nanoparticles and visualized via
confocal microscopy. Results showed no internalization of
the carboxylated nanoparticle (2) as expected (FIG. 4A, 4D).
However, significant internalization of the folate-conjugated
nanoparticle (4) was indicated by the presence of intense
fluorescence in the cytoplasm of the cells (FIG. 4B, 4E).
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folate-conjugated (4-DiR) IONPs (1.1 mg/mL) for 3 h. Next,
the cells were washed with PBS and detached with trypsin.
After centrifugation, the resulting cell pellets were simultaneously imaged using an indocyanine green (ICG) filter. No
cell-associated near infrared fluorescence was observed in
cells treated with the carboxylated (2-DiR) nanoparticles
(FIG. 16 panel A). In contrast, a dose-dependent cell-associated DiR fluorescence was observed in cells treated with the
folate-conjugated (4-DiR) nanoparticles (FIG. 16 panel B).
Since the cells were extensively washed with PBS before
imaging and considering the confocal microscopy results
shown in FIG. 4, it is plausible that the cells have internalized
the (4-DiR) nanoparticles via folate-receptor-mediated
endocytosis, thus endowing these cells with near infrared
fluorescent. To further confirm the association of these nanoparticles with folate-expressing A549 carcinoma cells, the
cell pellets were re-suspended in PBS and their fluorescence
emission and MRI signal (T2 relaxation time) were recorded.
An increase in fluorescence emission intensity and decrease
in magnetic relaxivity (T2) was observed from the corresponding suspension of the cell pellets (Table 3). No fluorescence emission or T2 changes were observed in H9c2 cardiomyocytes treated with 4-DiR. Therefore, these results
indicate that our targeted multimodal nanoparticles can
simultaneously allow the near infrared fluorescence and MR
imaging of folate-receptor expressing cells.

when conjugated with folic acid (using "click" chemistry)
provide targeted drug delivery to cancer cells that overexpress
the folate receptor, while avoiding normal cells that do not
overexpress this receptor. We suggest that this multimodal
(magnetic and fluorescent) and multifunctional (imaging and
therapeutic) IONPs will open many exciting opportunities for
the targeted delivery of therapeutic agents to tumors. In addition, the dual optical and magnetic properties of the synthesized nanoparticles will allow for the dual fluorescence- and
MR-based imaging and monitoring of drug efficacy. All these
positive attributes make the functional IONPs a promising
drug delivery vehicle for further in vivo evaluation.
With the foregoing in mind, those skilled in the art should
recognize that when we speak of a "metallic core" we intend
a core containing a metal, in any form. Also, the skilled will
understand that the hydrophobic pocket(s) formed by the
polymeric coat may accept for nesting therein any dye or drug
which is compatible with that characteristic, for example, a
dye or drug having at least a hydrophobic or lipophilic moiety; it is reasonable to prophetically predict that such dyes and
drugs will also work in the invention in addition to those
which have been disclosed herein as examples. Dyes which
are predicted to work in the invention include, without limitation, cardiogreen, quantum dots, Cy5, Cy5.5, and Alexafluor dyes to mention a few. Metals which are contemplated
to work in the invention include the following, although not
exclusively, cerium, gold, silver, bismuth, platinum, palladium and their oxides. It should also be understood that in
addition to folate groups, amine groups and alcohol groups
may also be conjugated on the nanoparticles to provide different targeting specificities. Regarding other drugs which are
predicted to work in the invention, these would include antiHIV drugs, anti-inflammatory drugs, AzT, camptothecin,
doxorubicin and others having hydrophobic groups.
Accordingly, in the drawings and specification there have
been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the
terms are used in a descriptive sense only and not for purposes
of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims, as set forth below.
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Determination of fluorescence emission intensity (a.u.) and
magnetic relaxivity (T2) of!ONP-(4-DiR)-treated cells
A549 in PBS.
A549 Cell
pellets

Cells
only

Cells+ 20
µLIONPs

Cells+ 40
µLIONPs

0.0
2000

1.7
165

2.0
126

Cells + 60 Cells + 80
µL IONPs µL IONPs
35

Fl. Emission (x10 5 )
T2 (ms)

2.4
101

2.7
78

To further assess the utility of the multimodal nanoparticle
4 encapsulating either DiI (4-DiI) or DiR (4-DiR), fluorescence and MRI studies were performed. First, phantoms containing both nanoparticles in PBS were taken using a dedicated optical imaging animal scanner (Maestro, CIR,
Woburn, Mass.). Results indicated the potential use of the
4-DiR nanoparticle for near infrared imaging, even in a nanoparticle suspension containing both 4-DiI and 4-DiR IONPs
(FIGS. 17A-E). These results are important as they point to
the possibility of simultaneously imaging both nanoparticles,
which could be utilized in the imaging of two different targets
in in vivo experiments (e.g. 2 different cell populations).
Furthermore, magnetic resonance imaging (MRI) studies of
4-DiI and 4-DiRnanoparticle dilutions (FIG.18) using a 4.7T
MRI scanner (Bruker, Bellerica Mass.) further demonstrated
the ability of these IONPs to behave as sensitive MRI contrast
agents.
In conclusion, we introduce a new method to synthesize
multimodal and theranostic PAA-IONPs for the potential in
vivo target-specific detection and treatment of tumors. Our
novel IONPs are biocompatible and biodegradable, as they
are synthesized from biodegradable and biocompatible components. These functional IONPs are stable in aqueous buffered solutions, possess good cellular targeting ability, and
their simple synthesis process is amenable to scale-up. In
addition, this method can easily be used to generate libraries
of targeted theranostic nanoparticles with different targeting
ligands or encapsulated agents, and even include different
metallic cores. Furthermore, the drug-encapsulating IONPs
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22. A method of treatment comprising contacting a dis40 eased cell with the nanoparticle of claim 1 which has been
That which is claimed:
conjugated with a ligand specific for a receptor expressed by
1. A nanoparticle comprising:
the diseased cell and wherein the drug is effective for treating
a metallic core;
the disease afflicting the cell.
a polymeric coat surrounding said core and forming an
23. The method of claim 22, further comprising tracking
outer periphery of said nanoparticle;
a plurality of hydrophobic pockets formed by the poly- 45 the nanoparticle by magnetic resonance imaging.
meric coat;
24. The method of claim 22, further comprising tracking
a plurality of carboxylic groups along an outer periphery of
the nanoparticle by optical imaging relying on fluorescence.
the polymeric coat and effective to conjugate with a
25.A water based, step-wise method of making polyacrylic
predetermined targeting ligand which functionalizes the
acid-coated iron oxide nanoparticles of claim 1, the method
nanoparticle;
50 comprising:
a lipophilic fluorescent dye encapsulated in the plurality of
preparing an aqueous solution of iron salts by mixing
FeC13 and FeC12 in dilute hydrochloric acid;
hydrophobic pockets; and
preparing an alkaline solution by dissolving anm10nium
a drug encapsulated in the plurality of hydrophobic pockets.
hydroxide in deionized water purged with nitrogen gas;
2. The nanoparticle of claim 1, wherein the metallic core 55
preparing a coating agent solution by dissolving polyacrylic acid in deionized water;
comprises a metallic oxide.
3. The nanoparticle of claim 1, wherein the metallic core
reacting by mixing the iron salts solution with the alkaline
comprises superparamagnetic iron oxide.
solution while vigorously stirring the mixture to form a
4. The nanoparticle of claim 1, wherein said polymeric coat
dark suspension of iron oxide nanoparticles;
comprises a biodegradable polymer.
60
adding coating agent solution while stirring;
5. The nanoparticle of claim 1, wherein said polymeric coat
separating the iron oxide nanoparticles from the suspension;
comprises a matrix of polyacrylic acid.
washing the separated nanoparticles in water to minimize
6. The nanoparticle of claim 1, wherein said polymeric coat
free polyacrylic acid and other unreacted reagents;
comprises a biodegradable polymer effective for forming a
purifying the washed nanoparticles through a magnetic
plurality of hydrophobic pockets.
65
column; and
7. The nanoparticle of claim 1, wherein folate groups are
concentrating the purified nanoparticles.
conjugated to the polymeric coat.
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26. A method of making polyacrylic acid-coated iron oxide

nanoparticles of claim 1, the method comprising:
reacting an acidic solution containing Fe+2 and Fe+3 ions
with aqueous ammonium hydroxide to form a dark suspension of iron oxide nanoparticles;
mixing aqueous polyacrylic acid with the suspension of
iron oxide nanoparticles while stirring for a time suffi-

18
cient for the nanoparticles to become coated with the
polyacrylic acid;
separating coated iron oxide nanoparticles from the mixture; and
washing and concentrating the separated nanoparticles.
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